ADMA – Adma Biologics Inc
Float Short %
6.5
Margin Of Safety %
2
Put/Call OI Ratio
0.4
EPS Next Q Diff
0.03
EPS Last/This Y
-0.29
EPS This/Next Y
0.37
Price
16.1
Target Price
32.33
Analyst Recom
1.5
Performance Q
-25.42
Relative Volume
1.07
Beta
0.49
Ticker: ADMA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ADMA | 17 | 0.30 | 1.39 | 104751 |
| 2025-08-18 | ADMA | 17.62 | 0.36 | 1.55 | 79194 |
| 2025-08-19 | ADMA | 17.44 | 0.38 | 0.13 | 82052 |
| 2025-08-20 | ADMA | 17.3 | 0.38 | 0.11 | 82339 |
| 2025-08-21 | ADMA | 17.1 | 0.37 | 0.24 | 84565 |
| 2025-08-22 | ADMA | 17.81 | 0.36 | 0.40 | 85117 |
| 2025-08-25 | ADMA | 17 | 0.36 | 0.96 | 85469 |
| 2025-08-26 | ADMA | 17.09 | 0.36 | 0.71 | 85720 |
| 2025-08-27 | ADMA | 17.25 | 0.36 | 1.57 | 86041 |
| 2025-08-28 | ADMA | 17.38 | 0.37 | 3.62 | 86576 |
| 2025-08-29 | ADMA | 17.25 | 0.37 | 1.96 | 86770 |
| 2025-09-02 | ADMA | 17.2 | 0.37 | 0.39 | 86906 |
| 2025-09-03 | ADMA | 16.93 | 0.37 | 0.89 | 87073 |
| 2025-09-04 | ADMA | 16.9 | 0.37 | 1.08 | 86931 |
| 2025-09-05 | ADMA | 16.88 | 0.36 | 0.31 | 87372 |
| 2025-09-08 | ADMA | 16.42 | 0.37 | 4.09 | 87615 |
| 2025-09-09 | ADMA | 16.39 | 0.38 | 0.68 | 88439 |
| 2025-09-10 | ADMA | 15.74 | 0.38 | 4.93 | 90972 |
| 2025-09-11 | ADMA | 16.13 | 0.39 | 0.52 | 91398 |
| 2025-09-12 | ADMA | 16.1 | 0.40 | 0.69 | 91312 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ADMA | 17.00 | 6.7 | - | 0.56 |
| 2025-08-18 | ADMA | 17.62 | 6.7 | - | 0.56 |
| 2025-08-19 | ADMA | 17.44 | 6.7 | - | 0.56 |
| 2025-08-20 | ADMA | 17.31 | 6.7 | - | 0.56 |
| 2025-08-21 | ADMA | 17.10 | 6.7 | - | 0.56 |
| 2025-08-22 | ADMA | 17.81 | 6.7 | - | 0.56 |
| 2025-08-25 | ADMA | 17.00 | 6.7 | - | 0.56 |
| 2025-08-26 | ADMA | 17.10 | 6.7 | - | 0.56 |
| 2025-08-28 | ADMA | 17.38 | 6.7 | - | 0.56 |
| 2025-08-29 | ADMA | 17.30 | 6.7 | - | 0.56 |
| 2025-09-02 | ADMA | 17.19 | 6.7 | - | 0.56 |
| 2025-09-03 | ADMA | 16.91 | 6.7 | - | 0.56 |
| 2025-09-04 | ADMA | 16.91 | 6.7 | - | 0.56 |
| 2025-09-05 | ADMA | 16.87 | 6.7 | - | 0.56 |
| 2025-09-08 | ADMA | 16.42 | 6.7 | - | 0.56 |
| 2025-09-09 | ADMA | 16.38 | 6.7 | - | 0.56 |
| 2025-09-10 | ADMA | 15.76 | 6.7 | - | 0.56 |
| 2025-09-11 | ADMA | 16.11 | 6.7 | - | 0.56 |
| 2025-09-12 | ADMA | 16.10 | 6.7 | - | 0.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ADMA | -6.51 | 3.81 | 5.96 |
| 2025-08-18 | ADMA | -6.73 | 5.07 | 5.96 |
| 2025-08-19 | ADMA | -6.73 | 5.07 | 5.96 |
| 2025-08-20 | ADMA | -6.73 | 5.07 | 5.96 |
| 2025-08-21 | ADMA | -6.73 | 5.07 | 5.96 |
| 2025-08-22 | ADMA | -6.73 | 5.07 | 5.96 |
| 2025-08-25 | ADMA | -6.73 | 1.85 | 5.96 |
| 2025-08-26 | ADMA | -6.73 | 1.85 | 5.96 |
| 2025-08-27 | ADMA | -6.73 | 1.85 | 6.49 |
| 2025-08-28 | ADMA | -6.73 | 1.85 | 6.49 |
| 2025-08-29 | ADMA | -6.73 | 1.85 | 6.49 |
| 2025-09-02 | ADMA | -6.73 | 3.28 | 6.49 |
| 2025-09-03 | ADMA | -6.73 | 3.28 | 6.49 |
| 2025-09-04 | ADMA | -6.73 | 3.28 | 6.49 |
| 2025-09-05 | ADMA | -6.73 | 3.28 | 6.49 |
| 2025-09-08 | ADMA | -6.73 | 3.09 | 6.49 |
| 2025-09-09 | ADMA | -6.73 | 3.09 | 6.49 |
| 2025-09-10 | ADMA | -6.73 | 3.09 | 6.49 |
| 2025-09-11 | ADMA | -6.73 | 3.09 | 6.50 |
| 2025-09-12 | ADMA | -6.73 | 3.09 | 6.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.15
Avg. EPS Est. Current Quarter
0.16
Avg. EPS Est. Next Quarter
0.18
Insider Transactions
-6.73
Institutional Transactions
3.09
Beta
0.49
Average Sales Estimate Current Quarter
131
Average Sales Estimate Next Quarter
137
Fair Value
16.42
Quality Score
99
Growth Score
80
Sentiment Score
3
Actual DrawDown %
37.3
Max Drawdown 5-Year %
-63.1
Target Price
32.33
P/E
18.97
Forward P/E
18.17
PEG
0.62
P/S
8.11
P/B
9.68
P/Free Cash Flow
58.45
EPS
0.85
Average EPS Est. Cur. Y
0.56
EPS Next Y. (Est.)
0.93
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
44.06
Relative Volume
1.07
Return on Equity vs Sector %
27.6
Return on Equity vs Industry %
40.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
ADMA Biologics IncSector: Healthcare
Industry: Biotechnology
Employees: 685
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
stock quote shares ADMA – Adma Biologics Inc Stock Price stock today
news today ADMA – Adma Biologics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ADMA – Adma Biologics Inc yahoo finance google finance
stock history ADMA – Adma Biologics Inc invest stock market
stock prices ADMA premarket after hours
ticker ADMA fair value insiders trading